Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ioanna Mavrommati

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Scientific Reports|March 18, 2016
Novel roles for class II Phosphoinositide 3-Kinase C2β in signalling pathways involved in prostate cancer cell invasionIoanna Mavrommati, Ouma Cisse, Marco Falasca, et al.
NPJ Breast Cancer|December 22, 2021
Subclonal heterogeneity and evolution in breast cancerIoanna Mavrommati, Flora Johnson, Gloria V Echeverria, et al.
Plos One|January 16, 2013
Class II phosphoinositide 3-kinases contribute to endothelial cells morphogenesisGianpaolo Tibolla, Roberto Piñeiro, Daniela Chiozzotto, et al.
Cell Reports|September 27, 2018
β-TrCP- and Casein Kinase II-Mediated Degradation of Cyclin F Controls Timely Mitotic ProgressionIoanna Mavrommati, Roberta Faedda, Giovanni Galasso, et al.
Journal of Experimental & Clinical Cancer Research : CR|November 23, 2019
Downregulation of class II phosphoinositide 3-kinase PI3K-C2β delays cell division and potentiates the effect of docetaxel on cancer cell growthOuma Cisse, Muzthahid Quraishi, Federico Gulluni, et al.
Cancer Cell|November 26, 2015
Inhibiting WEE1 Selectively Kills Histone H3K36me3-Deficient Cancers by dNTP StarvationSophia X Pfister, Enni Markkanen, Yanyan Jiang, et al.
Genome Medicine|April 9, 2026
Co-occurrence of transcriptionally distinct persister cell states underpins neoadjuvant therapy resistance in triple‑negative breast cancerYu Zhang, Fatemeh Ahmadi Moughari, Ioanna Mavrommati, et al.
Nature Genetics|July 31, 2023
SF3B1 hotspot mutations confer sensitivity to PARP inhibition by eliciting a defective replication stress responsePhilip Bland, Harry Saville, Patty T Wai, et al.
Cancer Research|January 29, 2021
3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast CancerBarrie Peck, Philip Bland, Ioanna Mavrommati, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Scientific Reports|March 18, 2016
Novel roles for class II Phosphoinositide 3-Kinase C2β in signalling pathways involved in prostate cancer cell invasionIoanna Mavrommati, Ouma Cisse, Marco Falasca, et al.
NPJ Breast Cancer|December 22, 2021
Subclonal heterogeneity and evolution in breast cancerIoanna Mavrommati, Flora Johnson, Gloria V Echeverria, et al.
Plos One|January 16, 2013
Class II phosphoinositide 3-kinases contribute to endothelial cells morphogenesisGianpaolo Tibolla, Roberto Piñeiro, Daniela Chiozzotto, et al.
Cell Reports|September 27, 2018
β-TrCP- and Casein Kinase II-Mediated Degradation of Cyclin F Controls Timely Mitotic ProgressionIoanna Mavrommati, Roberta Faedda, Giovanni Galasso, et al.
Journal of Experimental & Clinical Cancer Research : CR|November 23, 2019
Downregulation of class II phosphoinositide 3-kinase PI3K-C2β delays cell division and potentiates the effect of docetaxel on cancer cell growthOuma Cisse, Muzthahid Quraishi, Federico Gulluni, et al.
Cancer Cell|November 26, 2015
Inhibiting WEE1 Selectively Kills Histone H3K36me3-Deficient Cancers by dNTP StarvationSophia X Pfister, Enni Markkanen, Yanyan Jiang, et al.
Genome Medicine|April 9, 2026
Co-occurrence of transcriptionally distinct persister cell states underpins neoadjuvant therapy resistance in triple‑negative breast cancerYu Zhang, Fatemeh Ahmadi Moughari, Ioanna Mavrommati, et al.
Nature Genetics|July 31, 2023
SF3B1 hotspot mutations confer sensitivity to PARP inhibition by eliciting a defective replication stress responsePhilip Bland, Harry Saville, Patty T Wai, et al.
Cancer Research|January 29, 2021
3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast CancerBarrie Peck, Philip Bland, Ioanna Mavrommati, et al.
Pageof 1